Aerovate Therapeutics (AVTE) - Cash on Hand per Share

Aerovate Therapeutics (AVTE) is a biotech developer of pulmonary hypertension therapies whose resilience is based on attracting investment and successful clinical trials. Tracking the cash per share metric on GURU.Markets, we note that 2.63 determines the latest valuation figure. Demand for cardiovascular drugs is independent of economic conditions, and the potential addressable market possesses immense capacity due to a shortage of effective solutions.
Comprehensive metric breakdowns and analytics for Aerovate Therapeutics, Inc (AVTE)

Cash per share reflects the volume of liquid assets attributable to a single security. The formula measures the issuer's actual solvency, allowing for an assessment of the internal reserve available to cover liabilities. By analyzing fluctuations in cash per share, an investor can see the current value of 2.63. A high cash balance guarantees the financial stability of Aerovate Therapeutics (AVTE). This ensures the uninterrupted operation of protected temperature-controlled air corridors during the delivery of biopharmaceutical raw materials.